Argos aims to be a faithful servant of those fighting cancer and infectious diseases. The pharmaceutical firm's proprietary Arcelis platform uses biological components from the patient to create a white blood cell that triggers that patient's particular immune response. Its most promising candidate targets metastatic renal cell carcinoma, the most common kidney cancer. Argos also has an HIV treatment that is being funded by the NIH, a lupus antibody, and a treatment for psoriasis in the pipeline. The company manufactures its products at its North Carolina plant but will expand production into a new facility pending drug approval. Formed in 1997, Argos filed to go public in 2011 but withdrew in 2012.